TY - JOUR
T1 - Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer
AU - Ripping, T. M.
AU - Rammant, E.
AU - Witjes, J. A.
AU - Aaronson, N. K.
AU - van Hemelrijck, M.
AU - van Hoogstraten, L. M.C.
AU - Boormans, J.
AU - Goossens, C. A.
AU - van der Heijden, A. G.
AU - Hulshof, M.C.C.M.
AU - van Leenders, G. J.L.H.
AU - van Leliveld, A. M.
AU - Meijer, R. P.
AU - van Moorselaar, R. J.A.
AU - Mulder, S. F.
AU - Nooter, R. I.
AU - Noteboom, J. L.
AU - Oddens, J. R.
AU - de Reijke, T. M.
AU - van Rhijn, B. W.G.
AU - van Roermund, J. G.H.
AU - Smilde, T. J.
AU - Vanderbosch, G. W.J.
AU - Wijsman, B. P.
AU - Kiemeney, L. A.
AU - Aben, K. K.H.
N1 - Funding Information:
The BlaZIB study is funded by the Dutch Cancer Society (IKNL 2015–7914). The funding agency had no role in the design, data collection, analysis, and interpretation of the results of this study.
Funding Information:
We are grateful to all of the patients who participated in the BlaZIB study and thank all hospitals that were involved in the recruitment of patients. The authors also thank the research assistants for the HRQoL data collection and the registration team of the Netherlands Comprehensive Cancer Organisation (IKNL) for the collection of data from the Netherlands Cancer Registry. The members of the BlaZIB study group are: Dr. J. Boormans (Erasmus Medical Center), Dr. C.A. Goossens (Alrijne hospital), Dr. A.G. van der Heijden (Radboudumc), Dr. M.C.C.M. Hulshof (Amsterdam University Medical Centers, location AMC), Dr. G.J.L.H. van Leenders (Erasmus Medical Center), Dr. A.M. van Leliveld (University Medical Center Groningen), Dr. R.P. Meijer (University Medical Center Utrecht), Prof. dr. R.J.A. van Moorselaar (Amsterdam University Medical Centers, location VUmc), Dr. S.F. Mulder (Radboudumc), Dr. R.I. Nooter (St. Franciscus ziekenhuis), Dr. J.L. Noteboom (University Medical Center Utrecht), Dr. J.R. Oddens (Amsterdam University Medical Centers, location AMC), Dr. T.M. de Reijke (Amsterdam University Medical Centers, University of Amsterdam), Dr. B.W.G. van Rhijn (Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital), Dr. J.G.H. van Roermund (Maastricht University Medical Center), Dr. T.J. Smilde (Jeroen Bosch ziekenhuis), G.W.J. Vanderbosch (Patient association ‘Leven met blaas- of nierkanker’), Dr. B.P. Wijsman (Elizabeth-TweeSteden ziekenhuis).
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Background: Quality of Life (QoL) of bladder cancer patients has been largely neglected. This is partly due to the lack of well-validated QoL questionnaires. The aim of this study is to examine the structural validity, reliability (i.e., internal consistency and test-retest reliability), construct validity (i.e., divergent validity and known group validity) and responsiveness of the Dutch version of the European Organisation for Research and Treatment of Cancer QoL questionnaire for muscle invasive bladder cancer (EORTC-QLQ-BLM30). Methods: Patients with newly diagnosed muscle invasive bladder cancer (MIBC) participating in the population-based ‘Blaaskankerzorg In Beeld’ (BlaZIB) study who completed the EORTC-QLQ-BLM30 at baseline were included. BlaZIB is a Dutch nationwide population-based prospective cohort study collecting clinical data and QoL data of bladder cancer patients. QoL is assessed with a self-administered questionnaire at four points in time: 6 weeks (baseline), 6 months, 12 months and 24 months after diagnosis. Confirmatory factor analysis and multitrait scaling analysis were used to investigate and adapt the scale structure. Reliability, construct validity and responsiveness of the revised scales were evaluated. Results: Of the 1542 patients invited to participate, 650 patients (42.2%) completed the QLQ-BLM30 at baseline. The questionnaire’s scale structure was revised into seven scales and eight single items. Internal consistency and test-reliability were adequate for most scales (Cronbach’s α ≥0.70 and intraclass correlation coefficient ≥ 0.70, respectively), with the exception of the revised urostomy problem scale and abdominal bloating and flatulence scale. The questionnaire exhibited little overlap with the EORTC-QLQ-C30: all correlations were < 0.40, except for the correlation between emotional function (QLQ-C30) and future worries (QLQ-BLM30). The questionnaire was able to distinguish between patient subgroups formed on the basis of physical function, but not – as hypothesized– based on stage. Changes in health due to treatment were captured by the questionnaire, indicating that the questionnaire is responsive to change. Conclusions: This study shows that the adapted scale structure of the EORTC-QLQ-BLM30 generally exhibits good measurement properties in Dutch patients, but needs to be validated in other languages and settings. Trial registration: BlaZIB, NL8106, www.trialregister.nl.
AB - Background: Quality of Life (QoL) of bladder cancer patients has been largely neglected. This is partly due to the lack of well-validated QoL questionnaires. The aim of this study is to examine the structural validity, reliability (i.e., internal consistency and test-retest reliability), construct validity (i.e., divergent validity and known group validity) and responsiveness of the Dutch version of the European Organisation for Research and Treatment of Cancer QoL questionnaire for muscle invasive bladder cancer (EORTC-QLQ-BLM30). Methods: Patients with newly diagnosed muscle invasive bladder cancer (MIBC) participating in the population-based ‘Blaaskankerzorg In Beeld’ (BlaZIB) study who completed the EORTC-QLQ-BLM30 at baseline were included. BlaZIB is a Dutch nationwide population-based prospective cohort study collecting clinical data and QoL data of bladder cancer patients. QoL is assessed with a self-administered questionnaire at four points in time: 6 weeks (baseline), 6 months, 12 months and 24 months after diagnosis. Confirmatory factor analysis and multitrait scaling analysis were used to investigate and adapt the scale structure. Reliability, construct validity and responsiveness of the revised scales were evaluated. Results: Of the 1542 patients invited to participate, 650 patients (42.2%) completed the QLQ-BLM30 at baseline. The questionnaire’s scale structure was revised into seven scales and eight single items. Internal consistency and test-reliability were adequate for most scales (Cronbach’s α ≥0.70 and intraclass correlation coefficient ≥ 0.70, respectively), with the exception of the revised urostomy problem scale and abdominal bloating and flatulence scale. The questionnaire exhibited little overlap with the EORTC-QLQ-C30: all correlations were < 0.40, except for the correlation between emotional function (QLQ-C30) and future worries (QLQ-BLM30). The questionnaire was able to distinguish between patient subgroups formed on the basis of physical function, but not – as hypothesized– based on stage. Changes in health due to treatment were captured by the questionnaire, indicating that the questionnaire is responsive to change. Conclusions: This study shows that the adapted scale structure of the EORTC-QLQ-BLM30 generally exhibits good measurement properties in Dutch patients, but needs to be validated in other languages and settings. Trial registration: BlaZIB, NL8106, www.trialregister.nl.
KW - Bladder cancer
KW - EORTC questionnaire
KW - Patient-reported outcomes measures
KW - Quality of life
KW - Validation studies
UR - http://www.scopus.com/inward/record.url?scp=85145110637&partnerID=8YFLogxK
U2 - 10.1186/s12955-022-02064-z
DO - 10.1186/s12955-022-02064-z
M3 - Article
C2 - 36581934
AN - SCOPUS:85145110637
SN - 1477-7525
VL - 20
JO - Health and Quality of Life Outcomes
JF - Health and Quality of Life Outcomes
IS - 1
M1 - 171
ER -